Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Several previous case reports have shown that patients with immunoglobulin D (IgD) multiple myeloma (MM) can be withdrawn from hemodialysis, however, the characteristics that can predict withdrawal in these patients have not yet been elucidated. A 57-year-old Japanese woman required hemodialysis because of renal dysfunction due to IgD-λ and Bence Jones protein-λ MM. Bortezomib-based chemotherapy nine days after admission led to her withdrawal from hemodialysis on Day 50. In our case-based review, younger age and early initiation of bortezomib-based chemotherapy emerged as possible predictors of successful hemodialysis withdrawal.

Download full-text PDF

Source
http://dx.doi.org/10.18926/AMO/65154DOI Listing

Publication Analysis

Top Keywords

withdrawal hemodialysis
8
multiple myeloma
8
case-based review
8
bortezomib-based chemotherapy
8
withdrawal
4
hemodialysis patient
4
patient igd
4
igd type
4
type multiple
4
myeloma case-based
4

Similar Publications

Background: Cardiac troponin T is often elevated in hemodialysis patients, even without apparent heart disease. Cardiac troponin T has been used to predict mortality and morbidity among asymptomatic dialysis patients. However, only a single retrospective study has reported that higher IV iron use was associated with higher troponin levels; therefore, it remains unclear whether IV iron therapy could influence troponin levels and thus affect patients’ outcomes.

View Article and Find Full Text PDF

Background: Hemodialysis catheter dysfunction can arise from fibrin sheath formation, leading to impaired patency and compromised treatment. Tissue plasminogen activator (tPA) is an emerging treatment option to restore catheter patency. This study evaluated the efficacy of tPA therapy and explored clinical and demographic risk factors for catheter dysfunction.

View Article and Find Full Text PDF

Aim: To describe the demographics and comorbidities of people living with HIV (PLWH) starting on dialysis in Australia and New Zealand and to assess mortality outcomes and rates of infective complications.

Methods: Retrospective population-based cohort study of between 1996 and 2022. The primary outcome was the difference in survival between PLWH and HIV-negative patients started on dialysis.

View Article and Find Full Text PDF

Renal failure is considered a life-limiting CONDITION that often requires Renal Replacement Therapy, such as dialysis or kidney transplantation. Dialysis can effectively relieve symptoms and prolong life, but its withdrawal results in severe complications and death. The decision to discontinue or refuse to dialysis must be made collaboratively by the patient, family, and healthcare team, considering the clinical condition, life expectancy, symptom burden, and individual preferences.

View Article and Find Full Text PDF

Hemodialysis treatment, along with its therapeutic effects, can cause many physical, psychological, social, and spiritual problems including stress, anxiety and depression in patients. The aim of this study is to determine the relationship of spiritual orientation with depression and hopelessness in patients receiving hemodialysis treatment. This descriptive and correlation study included 72 patients undergoing hemodialysis.

View Article and Find Full Text PDF